Jim Simons
XERS icon

Jim Simons’s Xeris Biopharma Holdings XERS Stock Holding History

Jim Simons’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.63M Sell
452,860
-166,800
-27% -$1.11M ﹤0.01% 1735
2025
Q4 		$4.86M Sell
619,660
-1,003,180
-62% -$7.9M 0.01% 1324
2025
Q3 		$13.2M Sell
1,622,840
-432,500
-21% -$2.87M 0.02% 941
2025
Q2 		$9.6M Sell
2,055,340
-107,300
-5% -$492K 0.01% 1077
2025
Q1 		$11.9M Buy
2,162,640
+63,800
+3% +$258K 0.02% 917
2024
Q4 		$7.12M Buy
2,098,840
+500,120
+31% +$1.61M 0.01% 1224
2024
Q3 		$4.56M Buy
1,598,720
+247,080
+18% +$635K 0.01% 1506
2024
Q2 		$3.04M Buy
1,351,640
+342,300
+34% +$690K 0.01% 1604
2024
Q1 		$2.23M Sell
1,009,340
-372,300
-27% -$963K ﹤0.01% 1960
2023
Q4 		$3.25M Buy
1,381,640
+359,600
+35% +$664K 0.01% 1630
2023
Q3 		$1.9M Buy
1,022,040
+163,346
+19% +$374K ﹤0.01% 1899
2023
Q2 		$2.25M Buy
858,694
+254,800
+42% +$649K ﹤0.01% 1926
2023
Q1 		$984K Buy
603,894
+105,400
+21% +$132K ﹤0.01% 2487
2022
Q4 		$663K Sell
498,494
-51,200
-9% -$72.3K ﹤0.01% 2772
2022
Q3 		$858K Sell
549,694
-94,000
-15% -$155K ﹤0.01% 2589
2022
Q2 		$991K Sell
643,694
-49,300
-7% -$104K ﹤0.01% 2728
2022
Q1 		$1.77M Sell
692,994
-187,200
-21% -$457K ﹤0.01% 2320
2021
Q4 		$2.58M Buy
880,194
+738,182
+520% +$1.59M ﹤0.01% 1953
2021
Q3 		$348K Sell
142,012
-1,094,583
-89% -$3.18M ﹤0.01% 3030
2021
Q2 		$5.03M Buy
1,236,595
+178,932
+17% +$683K 0.01% 1636
2021
Q1 		$4.77M Buy
1,057,663
+955,314
+933% +$5.15M 0.01% 1676
2020
Q4 		$504K Buy
102,349
+37,254
+57% +$186K ﹤0.01% 2811
2020
Q3 		$386K Sell
65,095
-39,905
-38% -$160K ﹤0.01% 2916
2020
Q2 		$279K Sell
105,000
-282,516
-73% -$984K ﹤0.01% 3065
2020
Q1 		$756K Buy
+387,516
New +$1.67M ﹤0.01% 2567
2019
Q3 		– Sell
-19,700
Closed -$225K – 3752
2019
Q2 		$225K Buy
+19,700
New +$207K ﹤0.01% 3274

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jim Simons's XERS Position: Q1 2026 in Review

Jim Simons reduced its Xeris Biopharma Holdings (XERS) stake by 27% in Q1 2026, selling an estimated $1.11M and leaving 452,860 shares worth $2.63M. The position accounts for ﹤0.01% of the portfolio, ranked #1735.

Jim Simons first reported a position in XERS in Q2 2019 and has held it in 26 quarters since. The position peaked at $13.2M in Q3 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Jim Simons held 452,860 shares of Xeris Biopharma Holdings worth $2.63M as of Q1 2026.
  • Jim Simons sold 166,800 Xeris Biopharma Holdings shares in Q1 2026, an estimated $1.11M.
  • Xeris Biopharma Holdings made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #1735 holding.
  • Jim Simons first reported a position in Xeris Biopharma Holdings in Q2 2019 and has held it in 26 quarters since.
  • Jim Simons's Xeris Biopharma Holdings position peaked at $13.2M in Q3 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.